<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta name="study:id" content="icaht-scoring-comparison-zhang">
    <meta name="study:title" content="PB3488 - Can one scoring system fit all? A comparative evaluation of CAR-HEMATOTOX, ALL-HT, and EIPM for predicting immune effector cell-associated hematotoxicity (ICAHT) after CAR-T in hematological malignancies">
    <meta name="study:fileName" content="Abstracts/ICAHT-SCORING-COMPARISON-ZHANG.html">
    <meta name="study:cancerTypes" content="B-NHL">
    <meta name="study:lineOfTherapy" content="2L+">
    <meta name="study:evidenceType" content="Clinical trial">
    <meta name="study:drugs" content="CAR-T cell therapy,Axicabtagene ciloleucel">

    <title>PB3488: ICAHT Scoring System Comparison (Zhang) - SOBI Themed</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <script src="https://d3js.org/d3.v7.min.js"></script>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="abstract_styles.css"> </head>
<body class="abstract-page-body">
    <div class="slide-container">
        <div class="visual-abstract-container">
            <h2 class="visual-abstract-title">Visual Summary: PB3488 - Comparing ICAHT Predictive Models (CAR-HT, ALL-HT, eIPM) Post CAR-T</h2>
            <div class="visual-abstract-grid">
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path d="M12 6.096c-1.058 0-2.02.468-2.704 1.248-.685.78-.996 1.788-.996 2.856s.311 2.076.996 2.856C9.98 13.84 10.942 14.31 12 14.31s2.02-.468 2.704-1.248.996-1.788.996-2.856-.311-2.076-.996-2.856C14.02 6.564 13.058 6.096 12 6.096zM12 12.81c-.53 0-1.008-.222-1.352-.588-.344-.366-.528-.852-.528-1.422s.184-1.056.528-1.422C10.992 9.012 11.47 8.79 12 8.79s1.008.222 1.352.588.528.852.528 1.422-.184-1.056-.528 1.422C13.008 12.588 12.53 12.81 12 12.81zm6.708 3.672A7.47 7.47 0 0012.024 15c-1.404 0-2.706.39-3.816 1.056A4.476 4.476 0 004.5 19.686V21h15v-1.314a4.476 4.476 0 00-3.792-3.624zM6.024 16.56c.84-.468 1.848-.768 2.904-.924A5.928 5.928 0 0112.024 15a5.928 5.928 0 013.096.636c1.056.156 2.064.456 2.904.924A2.988 2.988 0 0019.5 18.018V19.5h-15v-1.482a2.988 2.988 0 001.524-2.458zM4.5 7.032c0-1.068.312-2.076.996-2.856S7.2 3 8.256 3A7.47 7.47 0 0112.024 1.5c1.404 0 2.706.39 3.816 1.056A4.476 4.476 0 0119.5 6.186V7.5H4.5v-.468zM18 4.56c-.84.468-1.848.768-2.904-.924A5.928 5.928 0 0012.024 6a5.928 5.928 0 00-3.096.636 7.524 7.524 0 00-2.904.924A2.988 2.988 0 014.5 7.482V6H3V4.5A1.5 1.5 0 014.5 3h15A1.5 1.5 0 0121 4.5V6h-1.5v1.482a2.988 2.988 0 01-1.524 2.458L18 4.56z" />
                    </svg>
                    <h4>Population & Aim (N=85)</h4>
                    <p>Pts with hematological malignancies (B-ALL, T-ALL/LBL, MM, AML) post CAR-T. Aim: Compare predictive performance of CAR-HT, ALL-HT, eIPM for ICAHT.</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path fill-rule="evenodd" d="M10.5 3.75a.75.75 0 01.75-.75h1.5a.75.75 0 01.75.75V4.5h3A2.25 2.25 0 0118.75 6.75v1.5a2.25 2.25 0 01-2.25 2.25H15.5V12h1.25a.75.75 0 010 1.5H15.5v1.5h.75a.75.75 0 010 1.5H15.5v1.5H18a.75.75 0 010 1.5h-2.5v1.5a.75.75 0 01-1.5 0V18h-1.5v1.5a.75.75 0 01-1.5 0V18h-1.5v1.5a.75.75 0 01-1.5 0v-3A2.25 2.25 0 016 14.25v-1.5A2.25 2.25 0 018.25 10.5H9.5V9H8.25A2.25 2.25 0 016 6.75v-1.5A2.25 2.25 0 018.25 3H10.5V3.75zm-1.5 6.75h6V6.75H9V10.5z" clip-rule="evenodd" />
                    </svg>
                    <h4>Methods</h4>
                    <p>Prospective analysis (2022-24). Calculated CAR-HT, ALL-HT, eIPM scores in acute leukemia & MM pts receiving CAR-T.</p>
                </div>
                <div class="visual-abstract-item">
                     <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path fill-rule="evenodd" d="M3.75 3A.75.75 0 003 3.75v16.5a.75.75 0 00.75.75h16.5a.75.75 0 00.75-.75V3.75a.75.75 0 00-.75-.75H3.75zm14.25 1.5H6v13.5h12V4.5zm-10.5 3a.75.75 0 000 1.5h9a.75.75 0 000-1.5h-9zm0 3.75a.75.75 0 000 1.5h9a.75.75 0 000-1.5h-9zm0 3.75a.75.75 0 000 1.5H9a.75.75 0 000-1.5H6z" clip-rule="evenodd" />
                    </svg>
                    <h4>Key Findings (ICAHT Prediction)</h4>
                    <p>All 3 scores identified high-risk ICAHT pts with prolonged neutropenia (e.g., CAR-HT: 18.4 vs 4.2 days, p < 1e-6). eIPM scores lower in ICAHT G<3 (p < 1e-6).</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path fill-rule="evenodd" d="M12 2.25c-5.385 0-9.75 4.365-9.75 9.75s4.365 9.75 9.75 9.75 9.75-4.365 9.75-9.75S17.385 2.25 12 2.25zm-.092 14.444a.75.75 0 01-.092 0l-3.75-3.75a.75.75 0 111.06-1.06L12 14.813l3.182-3.182a.75.75 0 111.06 1.06l-3.75 3.75a.75.75 0 01-.53.22z" clip-rule="evenodd" />
                    </svg>
                    <h4>Conclusion (Survival & Utility)</h4>
                    <p>Scores predict ICAHT well. For survival, integration with other parameters needed. ALL-HT high-risk B-ALL: shorter 1-yr DFS (36% vs 76%, p=0.031).</p>
                </div>
            </div>
        </div>

        <div class="text-center mb-8">
            <h1 class="abstract-header-title">PB3488 - Can one scoring system fit all? A comparative evaluation of CAR-HEMATOTOX, ALL-HT, and EIPM for predicting immune effector cell-associated hematotoxicity (ICAHT) after CAR-T in hematological malignancies</h1>
            <p class="abstract-sub-header">Ao-ran Zhang, Shang Qiannan, Xian-Ying Yin, et al.</p>
            <p class="abstract-meta-info mt-2">EHA 2025 Congress | Abstract #PB3488 | Publication Only</p>
        </div>

        <div class="grid md:grid-cols-2 gap-x-8 gap-y-6">
            <div> <div class="abstract-card">
                    <h2 class="abstract-section-title">Background</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Immune effector cell-associated hematotoxicity (ICAHT) significantly impacts survival after CAR-T therapy.</li>
                        <li>Existing predictive models:
                            <ul class="list-circle list-inside ml-4">
                                <li>CAR-HEMATOTOX (CAR-HT): For lymphoma and myeloma.</li>
                                <li>ALL-HEMATOTOX (ALL-HT): For B-cell Acute Lymphoblastic Leukemia (B-ALL).</li>
                                <li>Early ICAHT Prediction Model (eIPM).</li>
                            </ul>
                        </li>
                        <li>These models have not undergone systematic comparative evaluation across various hematological malignancies.</li>
                    </ul>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Aims</h2>
                    <p class="text-sm mb-1">This prospective analysis aimed to compare the predictive performance of three ICAHT models (CAR-HT, ALL-HT, eIPM) across different hematological malignancies.</p>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Methods & Study Design</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 mb-3 pl-2">
                        <li>Study Type: Prospective analysis.</li>
                        <li>Enrollment: Consecutive patients with hematological malignancies receiving commercial or experimental CAR-T cell therapy (2022-2024).</li>
                        <li>Patient Cohort (N=85):
                            <ul class="list-circle list-inside ml-4">
                                <li>B-ALL (N=35): CD19 CAR-T (14 KTE-19/Axicel).</li>
                                <li>T-ALL/LBL (N=17): CD7 CAR-T.</li>
                                <li>Multiple Myeloma (MM) (N=28): BCMA CAR-T.</li>
                                <li>Acute Myeloid Leukemia (AML) (N=5): LILRB4 cell therapy.</li>
                            </ul>
                        </li>
                        <li>Scoring: CAR-HT, ALL-HT, and eIPM scores calculated for patients with acute leukemia and MM.</li>
                        <li>Endpoints: Duration of neutropenia, incidence of ICAHT (grade >2), Overall Survival (OS), Disease-Free Survival (DFS).</li>
                    </ul>
                     <div class="study-design-schema">
                        <h3 class="schema-title">Comparative Evaluation of ICAHT Models</h3>
                        <div class="schema-enrollment">
                            <strong>Eligible Patients (N=85)</strong>
                            <span>Hematological Malignancies (B-ALL, T-ALL/LBL, MM, AML)</span>
                            <span>Received Commercial/Experimental CAR-T (2022-2024)</span>
                        </div>
                        <div class="schema-arrow-down">▼</div>
                        <div class="schema-phase-group justify-around">
                            <div class="schema-phase" style="flex-basis: 100%; background-color: var(--sobi-light-gray-bg); border-color: var(--sobi-dark-blue);">
                                <strong>Score Calculation & Risk Stratification</strong>
                                <span>CAR-HEMATOTOX (CAR-HT)</span>
                                <span>ALL-HEMATOTOX (ALL-HT) - for ALL/LBL Pts</span>
                                <span>Early ICAHT Prediction Model (eIPM - eIPMpre & eIPMpost)</span>
                            </div>
                        </div>
                        <div class="schema-arrow-down">▼</div>
                        <div class="schema-assessment-points">
                           <span>Duration of Neutropenia (ANC <500/μL)</span>
                           <span>Incidence of ICAHT (>Grade 2)</span>
                           <span>1-year Overall Survival (OS)</span>
                           <span>1-year Disease-Free Survival (DFS)</span>
                        </div>
                    </div>
                </div>
            </div> <div> <div class="abstract-card">
                    <h2 class="abstract-section-title">Results: Predictive Performance of ICAHT Models</h2>
                    <p class="text-sm mb-2">Total enrolled patients: 85. Median cumulative duration of ANC <500/μL (first 30 days): 14 days. 46 patients (54.1%) experienced ICAHT > Grade 2. No significant association found between ICAHT scores and severe CRS (≥G2) or ICANS (≥G2).</p>

                    <p class="text-sm font-semibold mt-3 mb-1">Neutropenia Duration by Risk Group:</p>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li><strong>CAR-HT (N=85):</strong> High-risk (n=66, 77.6%) vs. Low-risk (n=19, 22.4%)
                            <ul class="list-circle list-inside ml-4"><li>Duration: 18.4 vs. 4.2 days (p < 1×10⁻⁶).</li></ul>
                        </li>
                        <li><strong>ALL-HT (N=52 ALL/LBL):</strong> High-risk (n=34, 65.4%) vs. Low-risk (n=18, 34.6%)
                            <ul class="list-circle list-inside ml-4">
                                <li>Duration: 22.1 vs. 6.9 days (p < 1×10⁻⁶).</li>
                                <li>B-ALL Subgroup: 23.5 vs. 8.1 days (p < 0.0001).</li>
                                <li>T-ALL/LBL Subgroup: 18.7 vs. 5.1 days (p < 0.01).</li>
                            </ul>
                        </li>
                    </ul>
                     <p class="text-sm font-semibold mt-3 mb-1">eIPM Scoring System (N=85):</p>
                     <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Patients with ICAHT grade <3 had significantly lower scores than those with ICAHT grade 3-4 in:
                            <ul class="list-circle list-inside ml-4">
                                <li>eIPMpre model (p < 1×10⁻⁷).</li>
                                <li>eIPMpost model (p < 1×10⁻⁶).</li>
                            </ul>
                        </li>
                         <li>(Abstract notes specific percentages for eIPMpre [36.9% vs 17.0%] and eIPMpost [36.3% vs 15.7%], likely referring to proportions of patients within score categories achieving certain ICAHT outcomes, confirming lower scores for less severe ICAHT).</li>
                    </ul>

                    <p class="text-sm font-semibold mt-3 mb-1">Survival Outcomes (1-year):</p>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li><strong>CAR-HT Cohort:</strong>
                            <ul class="list-circle list-inside ml-4">
                                <li>OS: High-risk 79% vs. Low-risk 73% (p=0.6, NS).</li>
                                <li>DFS: High-risk 49% vs. Low-risk 71% (p=0.068, trend).</li>
                            </ul>
                        </li>
                        <li><strong>ALL-HT Cohort (ALL/LBL Pts):</strong>
                            <ul class="list-circle list-inside ml-4">
                                <li>OS: High-risk 69% vs. Low-risk 63% (p=0.5, NS).</li>
                                <li>DFS: High-risk 34% vs. Low-risk 58% (p=0.071, trend).</li>
                                <li>DFS in B-ALL (ALL-HT): High-risk 36% vs. Low-risk 76% (p=0.031, significant).</li>
                            </ul>
                        </li>
                    </ul>
                    <div class="abstract-card mt-4">
                        <h3 class="text-md font-semibold mb-2 text-center" style="color: var(--sobi-dark-blue);">Figure: Patient Characteristics, ICAHT Scores, and Survival</h3>
                        <img src="Assets/Zhang_EHA2025.jpg" alt="Figure: Patient characteristics, disease distribution, neutropenia duration by risk scores, eIPM scores, and survival curves." class="mx-auto rounded-lg shadow-md" style="max-width: 100%; height: auto;">
                        <p class="text-xs text-center mt-2 italic">Figure: Overview of patient data, risk stratification by CAR-HEMATOTOX and ALL-HT, association with neutropenia, eIPM score performance, and survival outcomes.</p>
                    </div>
                </div>
            </div> </div> <div class="abstract-card mt-6">
            <h2 class="abstract-section-title">Summary & Conclusion</h2>
            <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                <li>CAR-HT, ALL-HT, and eIPM scores effectively identified patients at high risk for ICAHT with prolonged neutropenia post-CAR-T infusion across acute leukemia (B-ALL, T-ALL/LBL, AML) and Multiple Myeloma (MM).</li>
                <li>The models showed utility in emerging research areas like T-ALL/LBL and AML.</li>
                <li>While predictive for hematotoxicity, the prognostic utility of these scores for survival outcomes (OS, DFS) may require integration with additional parameters to enhance predictive precision.</li>
                <li>Notably, high-risk B-ALL patients identified by ALL-HT had significantly shorter 1-year DFS.</li>
            </ul>
        </div>

        <div class="abstract-card mt-6 abbreviations-list">
            <h2 class="abstract-section-title">Abbreviations</h2>
            <p>ALL, Acute Lymphoblastic Leukemia; ALL-HT, ALL-HEMATOTOX score; AML, Acute Myeloid Leukemia; ANC, Absolute Neutrophil Count; B-ALL, B-cell Acute Lymphoblastic Leukemia; BCMA, B-Cell Maturation Antigen; CAR-HT, CAR-HEMATOTOX score; CAR-T, Chimeric Antigen Receptor T-cell; CD, Cluster of Differentiation; CRS, Cytokine Release Syndrome; DFS, Disease-Free Survival; eIPM, Early ICAHT Prediction Model; G, Grade; ICAHT, Immune Effector Cell-Associated Hematotoxicity; ICANS, Immune Effector Cell-Associated Neurotoxicity Syndrome; KTE-19, Axicabtagene Ciloleucel; LBL, Lymphoblastic Lymphoma; LILRB4, Leukocyte Immunoglobulin-Like Receptor B4; MM, Multiple Myeloma; NS, Not Significant; OS, Overall Survival; Pts, Patients; T-ALL, T-cell Acute Lymphoblastic Leukemia.</p>
        </div>

        <div class="abstract-card mt-6 reference-section">
            <h2 class="abstract-section-title">
                Reference
                <button id="copyReferenceBtn" class="copy-reference-button" title="Copy Reference">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor">
                        <path d="M7 3.5A1.5 1.5 0 018.5 2h3.879a1.5 1.5 0 011.06.44l3.122 3.121A1.5 1.5 0 0117 6.621V16.5a1.5 1.5 0 01-1.5 1.5h-7A1.5 1.5 0 017 16.5v-13z" />
                        <path d="M4.5 6A1.5 1.5 0 003 7.5v10A1.5 1.5 0 004.5 19h7a1.5 1.5 0 001.5-1.5v-2.5a.75.75 0 00-1.5 0v2.5a.5.5 0 01-.5.5h-7a.5.5 0 01-.5-.5v-10a.5.5 0 01.5-.5h2.5a.75.75 0 000-1.5H4.5z" />
                    </svg>
                    Copy
                </button>
            </h2>
            <p id="referenceSectionContent">Zhang A, Qiannan S, Yin XY, et al. Can one scoring system fit all? A comparative evaluation of CAR-HEMATOTOX, ALL-HT, and EIPM for predicting immune effector cell-associated hematotoxicity (ICAHT) after CAR-T in hematological malignancies. Abstract #PB3488 presented at European Haematology Association (EHA) June 12–15, 2025, Milan, Italy.</p>
        </div>

        <div class="abstract-footer-info">
            <p>EHA 2025 Congress | Abstract #PB3488 | Abstract Release: 05/14/2025 | Presentation: 06/12/2025</p>
            <p>For Research & Informational Purposes Only.</p>
        </div>
    </div> <script defer src="abstract_features.js"></script>
    </body>
</html>
